Inactivation of bone morphogenetic protein 2 may predict clinical outcome and poor overall survival for renal cell carcinoma through epigenetic pathways

ONCOTARGET Volume 6 Issue 11 Page 9577-9591 published_at 2015-04-20
アクセス数 : 1378
ダウンロード数 : 0

今月のアクセス数 : 50
今月のダウンロード数 : 0
Title
Inactivation of bone morphogenetic protein 2 may predict clinical outcome and poor overall survival for renal cell carcinoma through epigenetic pathways
Creator
Mitsui Yozo
Hirata Hiroshi
Arichi Naoko
Chang Inik
Fukuhara Shinichiro
Yamamura Soichiro
Shahryari Varahram
Deng Guoren
Saini Sharanjot
Majid Shahana
Dahiya Rajvir
Tanaka Yuichiro
Source Title
ONCOTARGET
Volume 6
Issue 11
Start Page 9577
End Page 9591
Journal Identifire
EISSN 1949-2553
Subjects
bone morphogenetic protein 2; renal cell carcinoma; DNA methylation; molecular marker ( Other)
Language
eng
Resource Type journal article
Publisher
IMPACT JOURNALS LLC
Date of Issued 2015-04-20
Access Rights metadata only access
Relation
[DOI] 10.18632/oncotarget.3445
[PMID] 25797254
Remark Address all correspondence and requests for Yozo Mitsui, MD, PhD, Departments of Urology, Shimane University Faculty of Medicine, 89-1 Enya-cho, 693-8501 Izumo, Japan. E-mail: mitsui@med.shimane-u.ac.jp. We thank Dr. Roger Erickson for his support and assistance with the preparation of the manuscript. This research study was supported by the National Center for Research Resources of the NIH through Grant Number RO1CA130860 and VA Merit Review and VA Program Project.